Determinants and Prevention of Coronary Disease in Patients With Chronic Kidney Disease.

[1]  P. Stenvinkel,et al.  Senescent Cells in Early Vascular Ageing and Bone Disease of Chronic Kidney Disease—A Novel Target for Treatment , 2019, Toxins.

[2]  A. Bagai,et al.  Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain–MI Registry , 2018, Journal of the American Heart Association.

[3]  K. Khunti,et al.  Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. , 2018, Diabetes research and clinical practice.

[4]  S. Lekawanvijit.  Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome , 2018, Toxins.

[5]  C. Daniel,et al.  Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation , 2018, International journal of nephrology.

[6]  Cheng-Li Lin,et al.  Impact of initial myocardial perfusion imaging versus invasive coronary angiography on outcomes in coronary artery disease: a nationwide cohort study , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  M. Tonelli,et al.  Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney DiseaseMineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update , 2018, Annals of Internal Medicine.

[8]  M. Lanaspa,et al.  Novel treatment strategies for chronic kidney disease: insights from the animal kingdom , 2018, Nature Reviews Nephrology.

[9]  G. London,et al.  Is progression of coronary artery calcification influenced by modality of renal replacement therapy? A systematic review , 2017, Clinical kidney journal.

[10]  Y. Kiuchi,et al.  Vitamin E-Coated Dialyzer Inhibits Oxidative Stress , 2017, Blood Purification.

[11]  L. Hsiao,et al.  α-Klotho expression determines nitric oxide synthesis in response to FGF-23 in human aortic endothelial cells , 2017, PloS one.

[12]  Masaya Takahashi,et al.  Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. , 2017, Kidney international.

[13]  M. Hu,et al.  Klotho/FGF23 Axis in Chronic Kidney Disease and Cardiovascular Disease , 2016, Kidney Diseases.

[14]  Christopher T. Chan,et al.  Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  B. Keating,et al.  Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients , 2015, Cardiorenal Medicine.

[16]  C. Herzog,et al.  Trends in Mortality Following Acute Myocardial Infarction Among Dialysis Patients in the United States Over 15 Years , 2015, Journal of the American Heart Association.

[17]  R. Sacco,et al.  Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Shaomin Li,et al.  New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials , 2015, PloS one.

[19]  Han Jun Cho,et al.  Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. , 2015, Journal of the American Society of Nephrology : JASN.

[20]  R. Foley,et al.  United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease , 2015, Kidney international supplements.

[21]  Darlene Dobkowski,et al.  The old is new: Lipid therapy and CKD , 2015, JAAPA : official journal of the American Academy of Physician Assistants.

[22]  J. Xie,et al.  Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. , 2015, Journal of the American Society of Nephrology : JASN.

[23]  M. Mohammadi,et al.  The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  A. Bello,et al.  Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  A. Schols,et al.  Chronic kidney disease and premature ageing , 2014, Nature Reviews Nephrology.

[26]  M. Tonelli,et al.  KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. , 2014, Kidney international.

[27]  C. Shanahan.  Mechanisms of vascular calcification in CKD—evidence for premature ageing? , 2013, Nature Reviews Nephrology.

[28]  M. Wolf,et al.  Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  P. Stenvinkel,et al.  Chronic kidney disease: a clinical model of premature aging. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  C. Shanahan.  Autophagy and matrix vesicles: new partners in vascular calcification. , 2013, Kidney international.

[31]  M. Kuro-o,et al.  Klotho and chronic kidney disease. , 2013, Contributions to nephrology.

[32]  M. Ketteler,et al.  FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  H. Sugiyama,et al.  A Decreased Level of Serum Soluble Klotho Is an Independent Biomarker Associated with Arterial Stiffness in Patients with Chronic Kidney Disease , 2013, PloS one.

[34]  M. Kuro-o,et al.  Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. , 2013, Annual review of physiology.

[35]  C. Shanahan,et al.  Mechanistic insights into vascular calcification in CKD. , 2013, Journal of the American Society of Nephrology : JASN.

[36]  Z. Massy,et al.  FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages , 2012, Osteoporosis International.

[37]  S. Devaraj,et al.  Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. , 2012, American journal of clinical pathology.

[38]  R. Foley,et al.  Long interdialytic interval and mortality among patients receiving hemodialysis. , 2011, The New England journal of medicine.

[39]  V. Shalhoub,et al.  Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. , 2011, Kidney international.

[40]  A. Papagianni,et al.  Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[42]  W. Richards,et al.  Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit Mineralization , 2011, Calcified Tissue International.

[43]  Z. Massy,et al.  Chronic kidney disease: Medial or intimal calcification in CKD—does it matter? , 2011, Nature Reviews Nephrology.

[44]  C. McIntyre,et al.  Dialysis-induced myocardial stunning: the other side of the cardiorenal syndrome. , 2011, Reviews in cardiovascular medicine.

[45]  A. Okayama,et al.  Plasma B-type natriuretic peptide level and cardiovascular events in chronic kidney disease in a community-based population. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[46]  C. McIntyre,et al.  Haemodialysis-Induced Myocardial Stunning in Chronic Kidney Disease – A New Aspect of Cardiovascular Disease , 2010, Blood Purification.

[47]  K. Tuttle,et al.  Longitudinal relationships among coronary artery calcification, serum phosphorus, and kidney function. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[48]  R. Foley,et al.  The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[49]  Christopher T. Chan.  Cardiovascular effects of home intensive hemodialysis. , 2009, Advances in chronic kidney disease.

[50]  B. Kestenbaum,et al.  Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[51]  L. Stevens,et al.  Coronary artery calcification scores in patients with chronic kidney disease prior to dialysis: reliability as a trial outcome measure. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  K. Chinnaiyan,et al.  Amplification of atherosclerotic calcification and Mönckeberg's sclerosis: a spectrum of the same disease process. , 2008, Advances in chronic kidney disease.

[53]  E. Imai,et al.  Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[54]  E. Unanue,et al.  Granzymes Drive a Rapid Listeriolysin O-Induced T Cell Apoptosis1 , 2008, The Journal of Immunology.

[55]  Peter Stenvinkel,et al.  Cytokine Dysregulation in Chronic Kidney Disease: How Can We Treat It? , 2008, Blood Purification.

[56]  Peter Stenvinkel,et al.  Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[57]  C. Sommerer,et al.  Cardiac Biomarkers in Haemodialysis Patients: The Prognostic Value of Amino-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T , 2007, Nephron Clinical Practice.

[58]  H. Katus,et al.  Cardiac biomarkers and survival in haemodialysis patients , 2007, European journal of clinical investigation.

[59]  J. Vandenbroucke,et al.  Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[60]  P. Raggi,et al.  Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. , 2005, Kidney international.

[61]  C. Ronco,et al.  Mononuclear leukocyte apoptosis in haemodialysis patients: the role of cell thiols and vitamin E. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[62]  P. Raggi,et al.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.

[63]  D. Memmos,et al.  Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[64]  D. Goldsmith,et al.  Coronary artery disease in uremia: Etiology, diagnosis, and therapy. , 2001, Kidney international.

[65]  M. Boaz,et al.  Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.

[66]  R. Foley,et al.  Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease and cardiac failure. Semin Dial 2003 , 2022 .

[67]  Tadashi Kaname,et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.

[68]  Eric D Weinhandl,et al.  Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[69]  M. Kuro-o,et al.  Klotho deficiency causes vascular calcification in chronic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[70]  C. Lam,et al.  N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. , 2007, Journal of the American Society of Nephrology : JASN.